Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

NCT06238921 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Triple Negative Breast Cancer

Interventions

RADIATION: Stereotactic Radiation
DRUG: Zimberelimab
DRUG: Sacituzumab govitecan

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]